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Introduction
It was not particularly noted as an occasion for celebration,
but the 13th meeting of the Breast Cancer Linkage Con-
sortium (BCLC) did mark the 10th anniversary of the Con-
sortium. Exactly 10 years ago, in November 1989, a small
group of cancer geneticists and epidemiologists convened
in Lyon, France, to initiate a joint effort with the aim being to
find breast cancer predisposition genes through linkage
analysis in multiple case families. Within a year, indepen-
dent work by Dr King (then at Berkeley University, Califor-
nia, USA) led to the discovery of linkage to the BRCA1
locus [1]. This provided a decisive incentive toward the
creation of what is now known as the BCLC database,
stimulating scientists to contribute linkage information to
replicate this finding [2]. Currently, this database holds
pedigree information on 1122 breast cancer families, and
includes data on health and carrier status, as well as
several thousand person-years of follow up. These pedi-
grees are from all over the world, and have been submitted
to the database by more than 75 research centres. Genetic
defects in BRCA1 or BRCA2 have been identified in 522
and 192 families, respectively. Linkage information at poly-
morphic markers flanking BRCA1 and BRCA2 is available
in almost 300 families. This database has allowed cumula-
tive estimates to be made of the cancer risks conferred by
mutations in BRCA1 [3] and BRCA2 [4,5]. Furthermore, it
has provided estimates of the proportions of families
affected by mutations in either gene, given a certain pheno-
type of the family as defined by the number of patients with
breast or ovarian cancer [4].
The Breast Cancer Linkage Consortium
database
Doug Easton (University of Cambridge, Cambridge, UK)
presented a number of recent analyses performed with the
database. The combination of linkage and mutation infor-
mation made it possible to estimate the sensitivity of muta-
tion testing as currently applied by many laboratories. For
BRCA1, a point estimate of 63% was derived, and 72%
for BRCA2. Thus, we are apparently still missing a sub-
stantial proportion of disease-related mutations. Partly, this
is due to technical limitations of the tests. Most testing
currently performed worldwide is based on polymerase
chain reaction, which misses large genomic rearrange-
ments and intronic variants that interfere with messenger
RNA processing. Sylvie Mazoyer (International Agency for
Research on Cancer, Lyon, France) showed us that about
15 genomic rearrangements are known today in BRCA1.
Depending on whether they display a founder effect in the
population under investigation, they may represent any-
where between 5–25% of all mutations found. She also
presented the results of a worldwide survey of the recently
detected 6-kilobase duplication of exon 13 in BRCA1,
and found it in 15 out of 3561 families tested, six of which
were identified in the UK. Undoubtedly, though, we are
also misclassifying unique missense variants as being of
‘unknown significance’. This problem can only be
addressed by assays that assess the functional relevance
of the DNA change.
Genotype–phenotype correlations
Analysis of the BCLC database also confirmed the pres-
ence of a genotype–phenotype correlation for both
BRCA1 and  BRCA2. Independent work by Bruce Ponder
(University of Cambridge, Cambridge, UK) showed earlier
that mutations in the carboxyl-terminal part of BRCA1, or
those in the middle third part of BRCA2, display altered
family-specific ratios of breast and ovarian cancer cases,
relative to mutations in the remainder of the genes [6,7].
Among non-Cambridge families in the database, this
effect was also seen, albeit with lower level of signifi-
cance. For the ovarian cancer cluster region in BRCA2,Breast Cancer Research    Vol 2 No 3 Devilee
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the evidence from 163 BRCA2-linked families suggested
that the ratio distortion is due to a reduced relative risk for
breast cancer in conjunction with an increased relative risk
for ovarian cancer, as compared with the nonovarian
cancer cluster region regions of BRCA2.
Modifiers of risk
There is currently much interest in whether the cancer
risks conferred by BRCA1 and BRCA2 mutations can be
modified by other factors, including genetic factors. The
evidence for such modifiers stems mainly from observa-
tions that cancer risk estimates derived from high-risk fam-
ilies differ from those from population-based studies, and
that cancer risks apparently differ substantially between
families and populations [8]. Despite some positive find-
ings [9,10], formal unbiased evidence that
BRCA1/BRCA2 risk-modifying genes exist is lacking, and
David Goldgar (IARC, Lyon, France) discussed the statis-
tical problems in finding them. Success strongly depends
on the extent of the conferred modifying effect [expressed
as relative risk (RR) or odds ratio]. If the RR is greater than
2.0, traditional linkage analysis in a well-defined set of
nuclear families may suffice. For smaller effects
(1.3<RR<2.0), association studies with candidate genes
seem to be the only way forward. Kate Nathanson (Univer-
sity of Pennsylvania School of Medicine, Philadelphia,
USA) presented some data using the former approach. An
initial finding of linkage with two markers on 5q in 19
BRCA1-linked families was lost on adding four new fami-
lies. Timothy Rebbeck (University of Pennsylvania School
of Medicine, Philadelphia, USA) presented work by a
North American Consortium of eight research groups,
using the alternative approach with 506 BRCA1 and 225
BRCA2 mutation carriers. They found that polymorphisms
in the AR, AIB1, GSTM1 and XRCC1 genes could signifi-
cantly modify breast cancer risks. These observations now
need replication in independent populations of carriers.
Doug Easton showed some power calculations indicating
that at least 500 cases are needed to detect a RR of 1.5,
and more than 1000 cases are needed to detect a RR of
1.3 at a significance level of 10–4.
Population studies
Much work on the prevalence of BRCA1 and BRCA2
mutations among breast and ovarian cancer cases unse-
lected for family history from populations with strong
founder effects at both genes has been published in
recent years. These mostly deal with the Ashkenazi Jewish
and Icelandic populations in which a few specific muta-
tions occur at high frequency. The data suggest that
BRCA1 and BRCA2 together largely explain the excess
familial breast cancer risk in these populations, and that
both genes confer considerably lower cancer risks than
previously estimated by the BCLC on high-risk families [8].
Few data are as yet available on populations in which
BRCA1 and BRCA2 mutations are less frequent, and
Paul Pharoah (CRC Human Cancer Genetics Group, Uni-
versity of Cambridge, Cambridge, UK) presented data on
the East Anglian population in the UK.  Among 1500 pop-
ulation-based breast cancer cases diagnosed before age
55 years, he found eight BRCA1 and 16 BRCA2 muta-
tions, which would only explain 17% of the excess familial
risk in this population. This is very similar to the estimates
obtained in other UK subpopulations [11]. The cumulative
breast cancer risks conferred by BRCA1 mutations were
slightly lower than those derived by the BCLC (ie approxi-
mately 50% by age 60 years), but for BRCA2 mutations
comparable estimates were found (approximately 70% by
age 60 years). Other investigators reported on similar
work that is as yet uncompleted, and is ongoing in The
Netherlands, Poland, Hungary, Sweden and Finland.
Other breast cancer predisposition genes
Clearly, there is considerable room for additional breast
cancer predisposing genes, and previous work by the
BCLC [4] has shown that, in particular, they may be found
among families without individuals with ovarian cancer or
male breast cancer, and only four or five breast cancer
cases. However, a linkage search carried out jointly by
David Goldgar and Mike Stratton (Institute of Cancer
Research, Belmont, Sutton, UK) in a subset of approxi-
mately 50 such BCLC families, which were carefully
selected for not being due to BRCA1 or BRCA2, has
remained negative so far. Assuming BRCA3 is the only
gene causing breast cancer in all these families, 89% of
the genome has been excluded for harbouring it with lod
scores lower than –2. Assuming that 50% of the examined
families are due to BRCA3, and the remainder due to
other genes, only 8% of the genome is excluded at the
same significance level. This illustrates the difficulty in
finding BRCA3, and the idea that ‘BRCA3’ actually con-
sists of an unknown number of different genes (BRCA3,
BRCA4,  BRCA5, etc) is therefore gaining weight. Olli
Kallioniemi (National Human Genome Research Institute,
Bethesda, USA) presented data from a Nordic/NHGRI
collaborative group, stressing the importance of character-
izing the breast tumours in non-BRCA1/BRCA2 linked
families by a combination of comparative genome
hybridization, loss of heterozygosity, immunohistochem-
istry and microarray analysis. In this way, specific somatic
genetic changes might be exploited to further subgroup
the non-BRCA1/BRCA2 families, thereby decreasing
genetic heterogeneity among them. Thus, this collabora-
tion has now collected 78 families for a linkage search,
and several preliminary hints for linkage are currently being
pursued further.
Pathology of BRCA-associated breast and
ovarian cancer
The BCLC resources have recently been extended with
sections and paraffin-embedded tumour tissues from over
300 breast and ovarian cancer patients from BCLC fami-3
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lies. Many of these patients are known carriers of BRCA1
or BRCA2 mutations, whereas others are from families
that probably harbour mutations in other genes. Sunil
Lakhani (University College London Medical School,
London, UK) is maintaining this resource, which has
already led to an accurate description of the BRCA1- and
BRCA2-linked morphology of breast cancer [12,13]. He
presented the results of immunophenotyping these
cancers, showing that BRCA1-, but not BRCA2-linked
tumours are often negative for oestrogen receptor and
progesterone receptor, relative to age-matched, appar-
ently sporadic cases. Approximately 40% of BRCA1-
related tumours showed positive p53-staining, which was
confirmed by two Italian studies (by Paolo Radice, Istituto
Nazionale, Tumori, Milan, Italy, and Maria Caligo, University
of Pisa, Pisa, Italy) that examined the presence of p53
gene mutations in BRCA1-related tumours. Non-
BRCA1/BRCA2 familial breast tumours are more often of
invasive lobular type (but only significantly so when com-
pared with the BRCA1-related cancers), and are overall of
lower grade than are sporadic tumours.
Low risk genes
The notion that certain polymorphisms in genes that are
involved in hormone or carcinogen metabolism, or in DNA
repair processes, might confer low risks to breast cancer
has attracted much attention. Although the identification of
such factors is not facilitated by the BCLC database, they
could explain major proportions of breast cancer in our pop-
ulation. Paul Pharoah presented a meta-analysis of 46 pub-
lished studies on this topic, indicating that most have
analyzed limited numbers of cases and that none of the 12
positive associations had been replicated by more than one
study [14]. After pooled analysis, only four associations
remained, all with RRs below 2: GSTM1 (homozygous null),
TP53 (72Pro),  GSTP1 (105Val) and CYP19 (TTTA10).
None of these could be replicated in his own population-
based study of almost 1200 cases (incident cases diag-
nosed at age below 65 years, and prevalent cases
diagnosed at age below 55 years) from East Anglia, UK.
Clinical dilemmas
Finally, a clinical research session illustrated how quickly
genetic knowledge on hereditary breast cancer has
moved to the bedside, but not without posing serious
dilemmas. All over the world, women attend cancer family
clinics to learn about their inherited cancer risks. Many of
the preventive options currently offered to a woman who
has been presymptomatically diagnosed as being a carrier
of a BRCA mutation remain without formal supporting evi-
dence, however. Difficulty in recruiting unbiased cohorts
of individuals or patients, or in performing proper prospec-
tive case–control studies hampers progress in this area.
Malcolm Pike (University of Southern California, Los
Angeles, USA), Mitch Dowsett (Royal Marsden Hospital,
London, UK), and Steven Narod (Women’s College Hos-
pital, Toronto, Canada) discussed chemoprevention
options. The choice of preventive agent is hotly debated,
and good prospective data on BRCA mutation carriers is
lacking. Timothy Rebbeck discussed prophylactic surgery,
which is intuitively the most secure way to reduce breast
cancer risk to below population levels. Although data on
its efficacy are emerging [15], this option is socially ill
accepted in many parts of the world, and formal proof of
its preventive effect in BRCA carriers is again still lacking.
For those who opt for a wait-and-see policy there are
uncertainties regarding treatment outcome as well.
William Foulkes (McGill University, Montreal, Quebec,
Canada) presented a summary of several studies to show
that some indicate no survival difference, whereas others
find a poorer survival in BRCA mutation carriers than in
noncarriers. Finally, Flora van Leeuwen (Netherlands
Cancer Institute, Amsterdam, The Netherlands) moderated
a discussion on how oral contraceptives might interact
with the breast and ovarian cancer risks conferred by
BRCA1 and  BRCA2 mutations.
Conclusion
The field of inherited susceptibility to breast cancer has
made a giant leap forward during the past decade, but
new challenges lie ahead. The BCLC has been extremely
successful in collating linkage and clinical data from fami-
lies with inherited breast cancer, enabling it to establish
cancer risks, genetic heterogeneity estimates and preva-
lence estimates for BRCA1 and BRCA2 mutations, and
other estimates. The search for additional susceptibility
genes will require very large numbers of highly selected
groups of multiple case families. Likewise, the search for
genetic modifiers of risk will require large numbers of
samples, as will the establishment of typical tumour char-
acteristics of cancers linked to BRCA1 or BRCA2 muta-
tions. The BCLC continues to provide an excellent
platform for such studies to be organized.
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